Position in CELC
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$12,063,228
-$3,225,816 QoQ
Shares Held
105,688
-31.1% QoQ
Ownership
0.216%
of shares outstanding
% of Portfolio
0.11%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2024
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CELC Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Walleye Capital LLC holds $328,656,270 across 126 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
126,005 | $33,608,053 | |
| 2 | CYTK |
Cytokinetics Inc
|
239,728 | $20,422,428 | |
| 3 | BMRN |
Biomarin Pharmaceutical Inc
|
288,233 | $16,492,692 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
386,183 | $14,393,040 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
22,596 | $14,089,509 | |
| 6 | RARE |
Ultragenyx Pharmaceutical Inc.
|
334,854 | $11,180,775 | |
| 7 | TYRA |
Tyra Biosciences, Inc.
|
347,898 | $11,111,862 | |
| 8 | BCAX |
Bicara Therapeutics Inc.
|
353,226 | $10,487,279 |
All Filings in CELC
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $12,063,228 | 105,688 | Shares | Sole | 2026-05-13 | |
| 2025-12-31 | $15,289,044 | 153,289 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $14,765,709 | 298,901 | Shares | Sole | 2025-11-14 | |
| 2024-03-31 | $544,773 | 25,221 | Shares | Sole | 2024-05-15 | |
| No filing history on record for this holder in this stock. | ||||||